BiosimilarDrug
BI 695500 clinical trials
Also written BI 695500.
A product of Rituximab; its studies count on that page too.
- studies test it
- 4
- open now
- 0
- in phase 3
- 3
- first study started
- 2012
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
4 studies that test it; most in 2013 (2)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2013 | 2 |
| 2015 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 0
Studies
Open first, then newest update. How each study uses BI 695500 is read from its arms, and is right about nine times in ten.
Testing it · 4
- Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Follicular LymphomaCompletedPhase 1Boehringer IngelheimNCT01950273Written as BI 695500
- Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid ArthritisTerminatedPhase 3Boehringer IngelheimNCT01682512Written as BI 695500
- Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid ArthritisTerminatedPhase 3Boehringer IngelheimNCT01955733Written as BI 695500
- BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular LymphomaTerminatedPhase 3Boehringer IngelheimNCT02417129Written as BI 695500